BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.05
$0.171.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.80M | -44.76M | -28.44M | -22.06M | -19.69M |
| Total Depreciation and Amortization | 194.00K | 181.00K | 181.00K | 54.00K | 52.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.86M | 8.82M | 486.00K | 944.00K | 200.00K |
| Change in Net Operating Assets | -6.49M | 6.99M | 4.48M | 1.46M | 4.40M |
| Cash from Operations | -42.23M | -28.77M | -23.29M | -19.60M | -15.04M |
| Capital Expenditure | -73.00K | -140.00K | -231.00K | -162.00K | -10.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.84M | 40.70M | 9.87M | 15.53M | 25.57M |
| Cash from Investing | 7.77M | 40.56M | 9.64M | 15.37M | 25.56M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.00K | 373.46M | -- | -- | 52.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | 0.00 | 22.22M | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -631.00K | -8.02M | -3.27M | -404.00K | -- |
| Cash from Financing | -586.00K | 365.44M | 18.96M | -404.00K | 52.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.05M | 377.22M | 5.30M | -4.64M | 10.57M |